Death · patients with Guillain‐Barré syndrome
1 finding from 1 review
Death · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death compared with placebo (very low certainty).
1 finding from 1 review
Death · patients with Guillain‐Barré syndrome
Cerebrospinal fluid filtration showed no clear difference in death compared with plasma exchange (low certainty).
1 finding from 1 review
Death · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death · adults or children with tuberculous meningitis on tuberculosis (TB) chemotherapy
Any corticosteroid leads to lower death compared with control (high certainty).
1 finding from 1 review
Intervention not reported
Death · Patients with dengue‐related shock
It is very uncertain whether the intervention changes death (very low certainty).
1 finding from 1 review
Intervention not reported
Death · Patients with dengue infection at an early stage
1 finding from 1 review
Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age among all randomised compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Death or disability after 1 year · patients with Guillain‐Barré syndrome
Corticosteroid showed no clear difference in death or disability after 1 year compared with control (moderate certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death or disability after 12 months compared with placebo (very low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Death Duration of trials: 8 to 24 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in death Duration of trials: 8 to 24 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 6 to 16 weeks · adults and adolescents with persistent asthma
The intervention showed no clear difference in death Duration of trials: 6 to 16 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Death Duration of trials: 12 to 13 weeks · adults and adolescents with persistent asthma
1 finding from 1 review
Death at hospital discharge · neonates with clinical and microbiological features of bacterial meningitis
It is very uncertain whether adjunctive steroid changes all‐cause death until hospital discharge compared with placebo (very low certainty).
1 finding from 1 review